AAPL278.95-14.22 (-4.85%) ▼|ABBV240.32+5.43 (+2.31%) ▲|ABT93.27+2.78 (+3.07%) ▲|ACN128.04-1.11 (-0.86%) ▼|ADBE196.05-0.51 (-0.26%) ▼|AMAT612.28+23.32 (+3.96%) ▲|AMD508.65-10.41 (-2.00%) ▼|AMGN356.43+5.04 (+1.43%) ▲|AMT170.59-3.87 (-2.22%) ▼|AMZN227.57-6.80 (-2.90%) ▼|AVGO373.11-8.97 (-2.35%) ▼|AXP346.57+4.01 (+1.17%) ▲|BA220.17-0.08 (-0.04%) ▼|BAC58.54+0.81 (+1.40%) ▲|BKNG181.20-0.08 (-0.04%) ▼|BLK992.40+9.80 (+1.00%) ▲|BMY55.82+0.82 (+1.49%) ▲|BNY145.38+1.82 (+1.27%) ▲|BRK-B492.35-2.47 (-0.50%) ▼|C145.88+2.29 (+1.59%) ▲|CAT1,025.38+30.93 (+3.11%) ▲|CL92.47+0.59 (+0.64%) ▲|CMCSA22.96+0.32 (+1.39%) ▲|COF205.25+4.77 (+2.38%) ▲|COP106.74-0.19 (-0.17%) ▼|COST953.58-7.39 (-0.77%) ▼|CRM151.56-1.21 (-0.79%) ▼|CSCO117.86-1.88 (-1.57%) ▼|CVS104.20+2.33 (+2.29%) ▲|CVX171.26-0.19 (-0.11%) ▼|DE616.54+15.79 (+2.63%) ▲|DHR195.10+6.23 (+3.30%) ▲|DIS100.85-0.27 (-0.27%) ▼|DUK128.04+1.51 (+1.19%) ▲|EMR145.55+4.11 (+2.91%) ▲|FDX324.33+7.50 (+2.37%) ▲|GD349.29+4.97 (+1.44%) ▲|GE373.62+7.74 (+2.12%) ▲|GEV1,057.62-0.03 (0.00%) ▼|GILD125.73+0.58 (+0.46%) ▲|GM79.41+0.46 (+0.58%) ▲|GOOG339.63-5.40 (-1.57%) ▼|GOOGL339.70-5.58 (-1.62%) ▼|GS1,078.54+1.63 (+0.15%) ▲|HD345.66+2.80 (+0.82%) ▲|HON234.50+7.08 (+3.11%) ▲|IBM260.38-2.59 (-0.98%) ▼|INTC126.67-5.24 (-3.97%) ▼|INTU259.00-3.34 (-1.27%) ▼|ISRG405.27+3.44 (+0.86%) ▲|JNJ246.22+5.22 (+2.17%) ▲|JPM338.27+4.82 (+1.45%) ▲|KO81.18+0.58 (+0.72%) ▲|LIN520.11+4.38 (+0.85%) ▲|LLY1,123.43+6.17 (+0.55%) ▲|LMT507.32+15.68 (+3.19%) ▲|LOW225.06+3.61 (+1.63%) ▲|LRCX373.25-1.58 (-0.42%) ▼|MA497.87+3.46 (+0.70%) ▲|MCD268.48-5.40 (-1.97%) ▼|MDLZ62.76+1.02 (+1.65%) ▲|MDT81.55+1.42 (+1.77%) ▲|META547.99-9.81 (-1.76%) ▼|MMM168.20+2.29 (+1.38%) ▲|MO73.27+1.20 (+1.66%) ▲|MRK123.11+2.51 (+2.08%) ▲|MS223.22+3.36 (+1.53%) ▲|MSFT357.36-8.09 (-2.21%) ▼|MU1,148.33+100.41 (+9.58%) ▲|NEE88.15+0.53 (+0.60%) ▲|NFLX72.53+0.69 (+0.95%) ▲|NKE41.63-0.19 (-0.45%) ▼|NOW90.67-3.13 (-3.34%) ▼|NVDA193.30-5.62 (-2.82%) ▼|ORCL151.91-5.63 (-3.57%) ▼|PEP142.82+0.55 (+0.39%) ▲|PFE24.18+0.14 (+0.56%) ▲|PG150.26-1.78 (-1.17%) ▼|PLTR107.58-5.94 (-5.23%) ▼|PM180.39+3.08 (+1.74%) ▲|QCOM203.21+5.89 (+2.98%) ▲|RTX188.25+3.19 (+1.72%) ▲|SBUX103.80+0.28 (+0.27%) ▲|SCHW91.63+0.24 (+0.26%) ▲|SO96.73+0.95 (+0.99%) ▲|SPG224.86+2.71 (+1.22%) ▲|T22.55+0.18 (+0.78%) ▲|TMO510.23+18.03 (+3.66%) ▲|TMUS182.00+1.21 (+0.67%) ▲|TSLA372.91-2.56 (-0.68%) ▼|TXN307.32+4.21 (+1.39%) ▲|UBER73.15-0.70 (-0.95%) ▼|UNH413.36+7.56 (+1.86%) ▲|UNP266.72+6.76 (+2.60%) ▲|UPS108.80+2.66 (+2.51%) ▲|USB61.40+1.29 (+2.15%) ▲|V335.18+2.95 (+0.89%) ▲|VZ45.93+0.25 (+0.55%) ▲|WFC85.65+1.35 (+1.60%) ▲|WMT118.25-0.77 (-0.64%) ▼|XOM137.34+0.44 (+0.32%) ▲|AAPL278.95-14.22 (-4.85%) ▼|ABBV240.32+5.43 (+2.31%) ▲|ABT93.27+2.78 (+3.07%) ▲|ACN128.04-1.11 (-0.86%) ▼|ADBE196.05-0.51 (-0.26%) ▼|AMAT612.28+23.32 (+3.96%) ▲|AMD508.65-10.41 (-2.00%) ▼|AMGN356.43+5.04 (+1.43%) ▲|AMT170.59-3.87 (-2.22%) ▼|AMZN227.57-6.80 (-2.90%) ▼|AVGO373.11-8.97 (-2.35%) ▼|AXP346.57+4.01 (+1.17%) ▲|BA220.17-0.08 (-0.04%) ▼|BAC58.54+0.81 (+1.40%) ▲|BKNG181.20-0.08 (-0.04%) ▼|BLK992.40+9.80 (+1.00%) ▲|BMY55.82+0.82 (+1.49%) ▲|BNY145.38+1.82 (+1.27%) ▲|BRK-B492.35-2.47 (-0.50%) ▼|C145.88+2.29 (+1.59%) ▲|CAT1,025.38+30.93 (+3.11%) ▲|CL92.47+0.59 (+0.64%) ▲|CMCSA22.96+0.32 (+1.39%) ▲|COF205.25+4.77 (+2.38%) ▲|COP106.74-0.19 (-0.17%) ▼|COST953.58-7.39 (-0.77%) ▼|CRM151.56-1.21 (-0.79%) ▼|CSCO117.86-1.88 (-1.57%) ▼|CVS104.20+2.33 (+2.29%) ▲|CVX171.26-0.19 (-0.11%) ▼|DE616.54+15.79 (+2.63%) ▲|DHR195.10+6.23 (+3.30%) ▲|DIS100.85-0.27 (-0.27%) ▼|DUK128.04+1.51 (+1.19%) ▲|EMR145.55+4.11 (+2.91%) ▲|FDX324.33+7.50 (+2.37%) ▲|GD349.29+4.97 (+1.44%) ▲|GE373.62+7.74 (+2.12%) ▲|GEV1,057.62-0.03 (0.00%) ▼|GILD125.73+0.58 (+0.46%) ▲|GM79.41+0.46 (+0.58%) ▲|GOOG339.63-5.40 (-1.57%) ▼|GOOGL339.70-5.58 (-1.62%) ▼|GS1,078.54+1.63 (+0.15%) ▲|HD345.66+2.80 (+0.82%) ▲|HON234.50+7.08 (+3.11%) ▲|IBM260.38-2.59 (-0.98%) ▼|INTC126.67-5.24 (-3.97%) ▼|INTU259.00-3.34 (-1.27%) ▼|ISRG405.27+3.44 (+0.86%) ▲|JNJ246.22+5.22 (+2.17%) ▲|JPM338.27+4.82 (+1.45%) ▲|KO81.18+0.58 (+0.72%) ▲|LIN520.11+4.38 (+0.85%) ▲|LLY1,123.43+6.17 (+0.55%) ▲|LMT507.32+15.68 (+3.19%) ▲|LOW225.06+3.61 (+1.63%) ▲|LRCX373.25-1.58 (-0.42%) ▼|MA497.87+3.46 (+0.70%) ▲|MCD268.48-5.40 (-1.97%) ▼|MDLZ62.76+1.02 (+1.65%) ▲|MDT81.55+1.42 (+1.77%) ▲|META547.99-9.81 (-1.76%) ▼|MMM168.20+2.29 (+1.38%) ▲|MO73.27+1.20 (+1.66%) ▲|MRK123.11+2.51 (+2.08%) ▲|MS223.22+3.36 (+1.53%) ▲|MSFT357.36-8.09 (-2.21%) ▼|MU1,148.33+100.41 (+9.58%) ▲|NEE88.15+0.53 (+0.60%) ▲|NFLX72.53+0.69 (+0.95%) ▲|NKE41.63-0.19 (-0.45%) ▼|NOW90.67-3.13 (-3.34%) ▼|NVDA193.30-5.62 (-2.82%) ▼|ORCL151.91-5.63 (-3.57%) ▼|PEP142.82+0.55 (+0.39%) ▲|PFE24.18+0.14 (+0.56%) ▲|PG150.26-1.78 (-1.17%) ▼|PLTR107.58-5.94 (-5.23%) ▼|PM180.39+3.08 (+1.74%) ▲|QCOM203.21+5.89 (+2.98%) ▲|RTX188.25+3.19 (+1.72%) ▲|SBUX103.80+0.28 (+0.27%) ▲|SCHW91.63+0.24 (+0.26%) ▲|SO96.73+0.95 (+0.99%) ▲|SPG224.86+2.71 (+1.22%) ▲|T22.55+0.18 (+0.78%) ▲|TMO510.23+18.03 (+3.66%) ▲|TMUS182.00+1.21 (+0.67%) ▲|TSLA372.91-2.56 (-0.68%) ▼|TXN307.32+4.21 (+1.39%) ▲|UBER73.15-0.70 (-0.95%) ▼|UNH413.36+7.56 (+1.86%) ▲|UNP266.72+6.76 (+2.60%) ▲|UPS108.80+2.66 (+2.51%) ▲|USB61.40+1.29 (+2.15%) ▲|V335.18+2.95 (+0.89%) ▲|VZ45.93+0.25 (+0.55%) ▲|WFC85.65+1.35 (+1.60%) ▲|WMT118.25-0.77 (-0.64%) ▼|XOM137.34+0.44 (+0.32%) ▲|
20.6 C
New York
Thursday, June 25, 2026

Tag: FDA

newssourceFORcompanyinformationcontent1marketreleases

PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy

               

WALL STREET RAISES RECORD BREAKING $4.2 MILLION AT 15TH ANNUAL LEVERAGED FINANCE FIGHTS MELANOMA BENEFIT SUPPORTING THE MELANOMA RESEARCH ALLIANCE

NEW YORK, June 13, 2025 /PRNewswire/ -- More than 1,100 private equity leaders, financiers and attorneys packed the Museum of Modern Art on June...

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard® Prime EPS.

Leading Independent Proxy Advisor Glass Lewis Recommends Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees

Independent proxy advisor Glass Lewis recommends that MediPharm shareholders vote for all of the Company's director nominees.

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

CLEVELAND, June 13, 2025 /PRNewswire/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in the TRANSFORM II randomized...

Weekly Recap: 11 Health Press Releases You Need to See

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including advances in sleep apnea treatments, fall detection for seniors...

Airis NEO P40000: Redefining Disposable Vapes, Delivering a Premium Experience of Pure and Smooth Vaping

SHENZHEN, China, June 13, 2025 (GLOBE NEWSWIRE) -- As a leading brand in the global vaping industry, Airis once again redefines industry expectations with the launch of its latest flagship product, the NEO P40000. This revolutionary product integrates an intelligent monitoring system, triple-core ultra-fast vaporization, five-level nicotine adjustment, and 15 authentic flavors, it not only redefines the user experience of disposable e-cigarettes but also leads global users into a new era of “smart, premium, and long-lasting” vaping.

Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease

TAINAN, June 12, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel...

PEPG Investor Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against PepGen Inc.

SAN DIEGO, June 12, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise...

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses

-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis...

4 Emerging Graft versus Host Disease Therapies That Could Change the Treatment Landscape | DelveInsight

Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation...

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Meeting to Reconvene on Wednesday, July 9, 2025 
Meeting to Reconvene on Wednesday, July 9, 2025

DBV Technologies to Participate in Upcoming EAACI Congress 2025

Châtillon, France, June 12, 2025

DBV Technologies participera au prochain congrès EAACI 2025

Châtillon, France, le 12 juin (22:30 CEST) 2025

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFDA

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers